Adagene (ADR)
Develops antibody cancer immunotherapies and licenses tumor-activated masking technology.
$3.68
After-hours close+0.02 (+0.55%)
At close$3.66(−6.15%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.23 | −$0.23 | 0.0% |
| Apr 2026 | −$0.28 | −$0.07 | +75.0% |
| Mar 2026 | −$0.19 | — | — |
| Mar 2025 | −$0.33 | −$0.55 | −67.7% |
| Jul 2024 | −$0.41 | −$0.19 | +53.0% |
The latest year is open to everyone — the 17 quarters behind it read with an account. Sign in | |||
| Mar 2024 | |||
| Mar 2024 | |||
| Sep 2023 | |||
| Aug 2023 | |||
| Mar 2023 | |||
| Mar 2023 | |||
| Sep 2022 | |||
| Aug 2022 | |||
| Sep 2021 | |||
| Aug 2021 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | −$0.23 | −$0.23 | 0.0% | $1.6M | $1.6M | 0.0% |
| Apr 1, 2026 | −$0.28 | −$0.07 | +75.0% | $17.5M | $7.7M | −56.1% |
| Mar 23, 2026 | −$0.19 | — | — | $17.5M | — | — |
| Mar 24, 2025 | −$0.33 | −$0.55 | −67.7% | — | $103.2K | — |
| Jul 25, 2024 | −$0.41 | −$0.19 | +53.0% | — | — | — |
The latest year is open to everyone — the 17 quarters behind it read with an account. Sign in | ||||||
| Mar 31, 2024 | ||||||
| Mar 29, 2024 | ||||||
| Sep 30, 2023 | ||||||
| Aug 31, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Mar 28, 2023 | ||||||
| Sep 30, 2022 | ||||||
| Aug 30, 2022 | ||||||
| Sep 30, 2021 | ||||||
| Aug 26, 2021 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||